Primary systemic amyloidosis
MONDO:0017816Primary systemic amyloidosis (PSA) is a form of AL amyloidosis caused by the aggregation and deposition of insoluble amyloid fibrils derived from misfolded monoclonal immunoglobulin light chains usually produced by a plasma cell tumor and characterized by multiple organ involvement.
Also known as: systemic AL amyloidosis, systemic Immunoglobulin Light chain amyloidosis, systemic amyloidosis
33 clinical trials for this condition and its sub-types, 22 tagged with Primary systemic amyloidosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug cocktail targets rare protein disease in early trial
Disease control CompletedThis early-phase trial tested a combination of three drugs—daratumumab, ixazomib, and dexamethasone—in 21 people with AL amyloidosis, a rare disease where abnormal protein builds up in organs. The main goal was to find the safest dose and check for side effects. Researchers also …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Promising combo therapy targets rare protein disease in major trial
Disease control CompletedThis study tested whether adding daratumumab to standard chemotherapy (CyBorD) helps people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. About 416 adults took part. The goal was to see if the combination leads to better blood res…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental antibody shows promise for rare amyloid disease
Disease control CompletedThis phase II trial tested the drug isatuximab in 43 patients with AL amyloidosis that had come back or stopped responding to treatment. Isatuximab is a monoclonal antibody that may help stop abnormal protein buildup. The study measured how well the drug reduced disease markers a…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC
-
A new scan aims to watch amyloid deposits in the body over time
Diagnosis CompletedThis study tests whether a special PET/CT scan can measure changes in amyloid deposits in organs of people with systemic amyloidosis. Participants receive an injection of a radiolabeled peptide that binds to amyloid, then undergo imaging at different times. Researchers compare th…
Phase 2 • Sponsor: University of Tennessee Graduate School of Medicine • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
Wrist MRI may spot hidden amyloid clumps without needles
Knowledge-focused CompletedThis study tested whether a special MRI scan of the wrist can detect amyloid deposits in people with systemic amyloidosis, a condition where abnormal proteins build up in organs. Researchers enrolled 128 adults, including patients with cardiac amyloidosis and healthy volunteers. …
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC